Trading was mixed on Monday with the S&P/TSX composite index closing down 64.48 points to 15,568.85 with cannabis stocks pulling down the health care sector 2.66 per cent. In the US, both the S&P 500 and Nasdaq added 0.1 per cent and the Dow Jones Industrial Average fell 0.2 per cent.
Trade talks between the US and China are resuming this week, making it a critical period ahead of an early March deadline which could see US tariffs on $200 billion worth of Chinese imports shoot up from ten to 25 per cent. Another issue with a looming timeline is Brexit, where the UK has until March 29 before its scheduled exit from the EU.
The result has been a case of the jitters for the markets, says Small, which comes after an optimistic start to 2019.
“January was making up for a lot of losses in December and here we are in February and I think the market and investors in general are taking a bit of a pause,” said Small, in conversation with BNN Bloomberg on Monday.
“I think that there are a lot of key political events coming up. Obviously, Washington now goes to China to continue the negotiations and the trade talks. We’ve heard recently that things aren’t going as well as maybe we’d like to hear and overall that things are a little ways away from coming up with some sort of a deal, and I think that has affected the market towards the end of last week,” he says.
So far in 2019, the Canadian market has been performing well against its American peers, with the S&P/TSX Composite index up 8.7 per cent compared to 8.1 per cent for the S&P 500 index while the Nasdaq has done the best, increasing by 10.1 per cent year-to-date.
Small predicts that a strong signal that a trade deal is likely will mean big gains for the market, somewhere between ten and fifteen per cent.
“It would be huge for the market,” he says.
“For someone like myself, I’ve kind of taken a bit of a pause for the moment. I want to see where things go, see what happens with the trade talks and then maybe be a buyer again. I think that if we do see a bit of a selloff, it could be a good opportunity to get into some names a lot cheaper,” he says.
Roth Capital Partners analyst Boobalan Pachaiyappan cut his target on ProMIS Neurosciences (ProMIS Neurosciences Stock Quote, Chart, News, Analysts, Financials… [Read More]
Roth Capital Partners analyst Philip Shen maintained his “Buy” rating and US$300.00 target on First Solar (First Solar, Stock Quote,… [Read More]
Roth Capital Partners analyst Bryan Baratian maintained his “Buy” rating and US$108.00 target on Hut 8 (Hut 8 Stock Quote,… [Read More]
Baskin Wealth Management president and chief investment officer Barry Schwartz named Topicus.com (Topicus.com Stock Quote, Chart, News, Analysts, Financials TSX:TOI)… [Read More]
On Oct. 29 Roth Capital Partners analyst Boobalan Pachaiyappan maintained his “Buy” rating and US$15.00 target on Atrium Therapeutics (Atrium… [Read More]
TD Cowen analyst David Kwan raised his target on Coveo Solutions (Coveo Solutions Stock Quote, Chart, News, Analysts, Financials TSX:CVO)… [Read More]